Humoral and Cell-mediated Immunity to Pandemic H1N1 Influenza in a Canadian Cohort One Year Post-pandemic: Implications for Vaccination
Overview
Authors
Affiliations
We evaluated a cohort of Canadian donors for T cell and antibody responses against influenza A/California/7/2009 (pH1N1) at 8-10 months after the 2nd pandemic wave by flow cytometry and microneutralization assays. Memory CD8 T cell responses to pH1N1 were detectable in 58% (61/105) of donors. These responses were largely due to cross-reactive CD8 T cell epitopes as, for those donors tested, similar recall responses were obtained to A/California 2009 and A/PR8 1934 H1N1 Hviruses. Longitudinal analysis of a single infected individual showed only a small and transient increase in neutralizing antibody levels, but a robust CD8 T cell response that rose rapidly post symptom onset, peaking at 3 weeks, followed by a gradual decline to the baseline levels seen in a seroprevalence cohort post-pandemic. The magnitude of the influenza-specific CD8 T cell memory response at one year post-pandemic was similar in cases and controls as well as in vaccinated and unvaccinated donors, suggesting that any T cell boosting from infection was transient. Pandemic H1-specific antibodies were only detectable in approximately half of vaccinated donors. However, those who were vaccinated within a few months following infection had the highest persisting antibody titers, suggesting that vaccination shortly after influenza infection can boost or sustain antibody levels. For the most part the circulating influenza-specific T cell and serum antibody levels in the population at one year post-pandemic were not different between cases and controls, suggesting that natural infection does not lead to higher long term T cell and antibody responses in donors with pre-existing immunity to influenza. However, based on the responses of one longitudinal donor, it is possible for a small population of pre-existing cross-reactive memory CD8 T cells to expand rapidly following infection and this response may aid in viral clearance and contribute to a lessening of disease severity.
Latest developments in early diagnosis and specific treatment of severe influenza infection.
Valenzuela-Sanchez F, Valenzuela-Mendez B, Rodriguez-Gutierrez J, Estella A J Intensive Med. 2024; 4(2):160-174.
PMID: 38681787 PMC: 11043645. DOI: 10.1016/j.jointm.2023.09.006.
Patil V, Hernandez-Franco J, Yadagiri G, Bugybayeva D, Dolatyabi S, Feliciano-Ruiz N Vaccines (Basel). 2023; 11(11).
PMID: 38006039 PMC: 10675483. DOI: 10.3390/vaccines11111707.
Role of the Host Genetic Susceptibility to 2009 Pandemic Influenza A H1N1.
Perez-Rubio G, Ponce-Gallegos M, Dominguez-Mazzocco B, Ponce-Gallegos J, Garcia-Ramirez R, Falfan-Valencia R Viruses. 2021; 13(2).
PMID: 33671828 PMC: 7926867. DOI: 10.3390/v13020344.
Law J, Koh W, Budylowski P, Lin J, Yue F, Abe K J Immunol. 2020; 206(1):37-50.
PMID: 33208459 PMC: 7750861. DOI: 10.4049/jimmunol.2001067.
A PBMC-Based System to Assess Human T Cell Responses to Influenza Vaccine Candidates In Vitro.
Tapia-Calle G, Born P, Koutsoumpli G, Gonzalez-Rodriguez M, Hinrichs W, Huckriede A Vaccines (Basel). 2019; 7(4).
PMID: 31766202 PMC: 6963913. DOI: 10.3390/vaccines7040181.